FDA loses power to verify biosimilar drugs are truly swappable
H.R. 5526 — Biosimilar Red Tape Elimination Act · Filed by August Pfluger (R-TX) · 10 cosponsors · Introduced Sep 19, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill eliminates the FDA's requirement that biosimilar drugs (generic versions of complex biologic medicines) prove they are 'interchangeable' with the original drug before being approved. Instead, all biosimilars approved after the bill's enactment are automatically deemed interchangeable 60 days after the law passes, unless an earlier biosimilar still holds an exclusivity period. The bill removes the FDA's discretion to require additional testing to confirm interchangeability and shifts the burden of proof away from manufacturers.
Why we flagged it
The bill's operative mechanism is the repeal of the FDA's interchangeability determination requirement, which is a deregulatory move that streamlines biosimilar approval by eliminating a substantive safety-verification gate. The title 'Red Tape Elimination' frames this as burden-reduction, but the substance is removal of a patient-protection standard.
What the text implies
- Automatic interchangeability status removes FDA's ability to require comparative clinical data proving a biosimilar can safely substitute for the reference product, shifting substitution risk to patients and pharmacists.
- Pharmacists and physicians will no longer have FDA-verified interchangeability determinations to guide substitution decisions; they must rely on biosimilarity alone, which is a lower bar.
- The 60-day transition period means biosimilars approved after enactment are immediately deemed interchangeable without any additional FDA review or public comment on substitutability.
- Existing exclusivity periods for first interchangeable biosimilars are preserved, but new biosimilars bypass the interchangeability gate entirely, creating a two-tier system where older biosimilars had higher scrutiny than new ones.
- The bill's conforming amendments strip references to 'interchangeability' from multiple FDA statutes, effectively erasing the interchangeability standard from the regulatory framework.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Patients lose FDA-verified confirmation that a biosimilar can safely substitute for the original biologic drug. While biosimilars remain subject to FDA approval as 'similar,' the interchangeability standard required additional comparative data to ensure substitution safety. Removing that gate reduces regulatory scrutiny of substitutability, benefiting manufacturers (lower approval costs, faster market entry) at the expense of patient safety assurance and pharmacist/physician confidence in automa
Who stands to gain
- biosimilar manufacturers
- generic/follow-on biologic drug companies
- pharmaceutical manufacturers seeking faster market entry
Named in the bill
FDA (Food and Drug Administration), HHS (Department of Health and Human Services), Section 351(k) of the Public Health Service Act, Section 352A of the Public Health Service Act, Section 744G(14) of the Federal Food, Drug, and Cosmetic Act, Section 505B(l) of the Federal Food, Drug, and Cosmetic Act
Where it stands
10 cosponsors: 6 Republicans, 4 Democrats.
- Sep 19, 2025 — Introduced · Congress.gov: “Introduced in House”
- Sep 19, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
21 lobbying clients named this bill on 23 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $10,920,000 in lobbying spend. A filing names 12 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 97% of bills with at least one filing.
August Pfluger, the sponsor, reported $1,070,325 in PAC receipts in the 2026 cycle. $17,000 of that came from 2 PACs tied to these lobbying clients.
- Amgen Inc — $2,440,000 on 1 filing
- Pfizer Inc. — $1,880,000 on 1 filing
- Johnson & Johnson Services Inc — $1,440,000 on 1 filing
- Association for Accessible Medicines — $870,000 on 1 filing
- Apotex Corp. — $730,000 on 1 filing
Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (8,187 characters) on Sep 7, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,398 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 22, 2026 · page rendered 2026-10-23.
“FDA loses power to verify biosimilar drugs are truly swappable” QuorumCivic. https://share.quorumcivic.app/bill/119/hr5526 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.